ARCHIVES

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Center Directors Urge NCI To Expand CTEP’s Treatment Referral Cntr.

March 12, 1993

Lynch Named Director, Yale Cancer Center

February 27, 2009

Judge Sentences Former BMS Exec Bodner To Write Book Reflecting On His Experience

June 12, 2009

DCE Advisors Approve New Grant Program On Lung Carcinoma

June 30, 1995

Tobacco Regulation: ACS Advocates Giving FDA Full Authority Over Tobacco

January 23, 1998

In Brief: Basic Science Center Funding Plan Clarified; Janice Feldman Leaves As Chief Of NIH Nursing

February 17, 1989